Department of Medicine

Department of Medicine

  Division of Gastroenterology, Hepatology and Nutrition

[Return To Index page]
photo Ian McGowan, MD, PhD, FRCP


Phone: 412-641-4710

Office: Div. of Gastro., Hepatology & Nutrition
204 Craft Ave.Room B505
Pittsburgh, PA 15213
Phone: 412-641-4710
Fax: 412-641-6170
Administrative Assistant:
Kathy McCarthy
Address: Division of Gastro, Hepatology & Nutrition
204 Craft Ave Rm B505
Pittsburgh, PA 15213
Phone: 412-641-8905
Fax: 412-641-6170
Education and Training
MBChB, Liverpool University Medical School, Liverpool, UK, 1985
DPhil, University of Oxford, Oxford, UK, 1998
MD, Liverpool School of Tropical Medicine, Liverpool, UK, 2014
FRCP, Royal College of Physicians, UK
Internal Medicine, Liverpool, UK, 1986
HIV Medicine, Middlesex Hospital, London, UK, 1989
Research Fellowship in Gastroenterology, Middlesex Hospital - London, England, 1991
Blinder Fellowship in Inflammatory Bowel Disease, UCLA, Los Angeles, 1994
Research Interest
Dr. McGowan is a Professor of Medicine whose research focuses on mucosal pathogenesis of HIV infection and development of topical products or microbicides to prevent the acquisition of HIV infection associated with vaginal or rectal sex. Dr. McGowan's lab has developed techniques to screen for microbicide-induced mucosal toxicity including multi-color flow cytometry, real time RT-PCR, and gene array studies, techniques now being used by other to explore the pathogenesis of gastrointestinal (GI) disorders including inflammatory bowel disease. The goal of this research program is to provide a translational toolbox to address multiple questions focused on the mucosal pathogenesis of GI diseases.
For my complete bibliography, Click Here.
Selected Publications:
Anton, P.A., Cranston, R.D., Kashuba, A., Hendrix, C.W., Bumpus, N.N., Richardson-Harman, N., Elliott, J., Janocko, L., Khanukhoba, E., Dennis, R., Cumberland, W.G., Ju, C., Carballo-Dieguez, A., Mauck, C., McGowan, I. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared to oral tenofovir disoproxil fumarate. AIDS Research and Human Retroviruses. 2012; 28(11): 1412-1421.
Matsumoto, H., Haga, K., Ohno, I., Hiraoka, K., Kimura, T., Hermann, K., Kasahara, N., Anton, P., McGowan, I. Mucosal gene therapy using a pseudotypes lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis. BMC Gastroenterology. 2014; 14: 68.
Marrazzo, J.M., Ramjee, G., Richardson, B., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabito, C., van der Straten, A., Noguchi, L., Hendrix, C.W., Dai, J.Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U., Piper, J., Masse, B., Grossman, C., Rooney, J. Tenofovir-based preexposure prohylaxis for HIV infection among African women. The New England Journal of Medicine. 2015; 372(2): 509-518.
Hladik, F., Burgener, A., Ballweber, L., Gottardo, R., Vojtech, L., Fourati, S., Dai, J.Y., Cameron, M.J., Strobl, J., Hughes, S.M., Hoesley, C., Andrew, P., Johnson, S., Piper, J., Friend, D.R., Ball, T.B., Cranston, R.D., Mayer, K.H., McElrath, M.J., McGowan, I. Mucosal effects of tenofovir 1% gel. Elife. 2015; 3: 4.
McGowan, I., Cranston, R.D., Duffill, K., Siegel, A., Engstrom, J.C., Nikiforov, A., Jacobson, C., Rehman, K.K., Elliott, J., Khanukhova, E., Abebe, K., Mauck, C., Spiegel, H.M., Dezzutti, C.S., Rohan, L.C., Marzinke, M.A., Hiruy, H., Hendrix, C.W., Richardson-Harman, N., Anton, P.A. A Phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 study). PLoS One. 2015; 10(5): e0125363.
McGowan, I., Anton, P.A., Elliott, J., Cranston, R.D., Duffill, K., Althouse, A.D., Hawkins, K.L., De Rosa, S.C. Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials. PLoS One. 2015; 10(5): e0126454.
Janocko, L., Althouse, A.D., Brand, R.M., Cranston, R.D., McGowan, I. The molecular characterization of intestinal explant HIV infection using PCR-based techniques. AIDS Research and Human Retroviruses. 2015; 31(10): 981-991.
Romas, L., Birse, K., Mayer, K.H., Abou, M., Westmacott, G., Giguere, R., Febo, I., Cranston, R.D., Carballo-Dieguez, A., McGowan, I., Burgener, A. Rectal 1% tenofovir gel use associates with altered epidermal protein expression. AIDS Research and Human Retroviruses. 2016.
Baeten, J.M., Palanee-Phillips, T., Brown, E.R., Schwartz, K., Soto-Torres, L.E., Govender, V., Mgodi, N.M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., Siva, S., Bekker, L.G., Jeenarain, N., Gaffoor, Z., Martinson, F., Makanani, B., Pather, A., Naidoo, L., Husnik, M., Richardson, B.A. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. The New England Journal of Medicine. 2016.
Sponsored Research/Activities
Title: Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI110410
Start Year: 2014
End Year: 2015
Title: Microbicides Trial Network
Role: Co-Investigator
Funding Agency: Magee Womens Hospital/National Institute of Allergy & Infectious Diseases
Start Year: 2007
End Year: 2013
Notable Achievements
Hopkins Endoscopy Prize of the British Society of Gastroenterology, 1988
Medical Research Council Training Fellowship, 1991
Blinder Research Fellowship in Crohn’s Disease, UCLA Medical School, Los Angeles, 1994
Gaspar de Portola Catalonian Studies Program Visiting Professorship, 2003
Sir Stanley Davidson Lecture of the Royal College of Physicians of Edinburgh, 2006
Chair of the Antiviral Drugs Advisory Committee of the United States Food and Drug Administration, 2008
hair of the Microbicide Advisory Committee, Population Council, New York, 2013
Member of the External Advisory Panel for the Bill and Melinda Gates Foundation Global Health HIV/AIDS portfolio, 2014